메뉴 건너뛰기
The Lancet Infectious Diseases
Volumn 17, Issue 9, 2017, Pages 898-
Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science
Author keywords

[No Author keywords available]
Indexed keywords

TUBERCULOSTATIC AGENT;
EID: 85027871310     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30449-8     Document Type: Letter
Times cited : (9)
References (7)
  • 1
    • 85019150326 scopus 로고    scopus 로고
    • Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study
    • Sharma, A, Hill, A, Kurbatova, E, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis 17 (2017), 707–715.
    • (2017) Lancet Infect Dis , vol.17 , pp. 707-715
    • Sharma, A.1    Hill, A.2    Kurbatova, E.3
  • 2
    • 85019161795 scopus 로고    scopus 로고
    • Drug-resistant tuberculosis threatens WHO's End-TB strategy
    • Mariandyshev, A, Eliseev, P, Drug-resistant tuberculosis threatens WHO's End-TB strategy. Lancet Infect Dis 17 (2017), 674–675.
    • (2017) Lancet Infect Dis , vol.17 , pp. 674-675
    • Mariandyshev, A.1    Eliseev, P.2
  • 3
    • 81055143909 scopus 로고    scopus 로고
    • Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability
    • Srivastava, S, Pasipanodya, JG, Meek, C, Leff, R, Gumbo, T, Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204 (2011), 1951–1959.
    • (2011) J Infect Dis , vol.204 , pp. 1951-1959
    • Srivastava, S.1    Pasipanodya, J.G.2    Meek, C.3    Leff, R.4    Gumbo, T.5
  • 4
    • 84990938502 scopus 로고    scopus 로고
    • Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis
    • Nahid, P, Dorman, SE, Alipanah, N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 63 (2016), e147–e195.
    • (2016) Clin Infect Dis , vol.63 , pp. e147-e195
    • Nahid, P.1    Dorman, S.E.2    Alipanah, N.3
  • 5
    • 84973465872 scopus 로고    scopus 로고
    • Incorporating therapeutic drug monitoring in WHO's hierarchy of tuberculosis diagnostics
    • Ghimire, S, Bolhuis, MS, Sturkenboom, MG, et al. Incorporating therapeutic drug monitoring in WHO's hierarchy of tuberculosis diagnostics. Eur Respir J 47 (2016), 1867–1869.
    • (2016) Eur Respir J , vol.47 , pp. 1867-1869
    • Ghimire, S.1    Bolhuis, M.S.2    Sturkenboom, M.G.3
  • 6
    • 85027890001 scopus 로고    scopus 로고
    • Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
    • Falzon, D, Jaramillo, E, Gilpin, C, Weyer, K, Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. Eur Respir J, 49, 2017, 1700317.
    • (2017) Eur Respir J , vol.49 , pp. 1700317
    • Falzon, D.1    Jaramillo, E.2    Gilpin, C.3    Weyer, K.4
  • 7
    • 84897144972 scopus 로고    scopus 로고
    • World Health Organization Geneva
    • WHO. The End TB Strategy, 2015, World Health Organization, Geneva.
    • (2015) The End TB Strategy

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.